The results of GSE114922 indicated that the expression levels of MAML3 and PLCB1 in patients with MDS-EB were significantly higher than those without EB (p < 0.001, p = 0.021, respectively) (Fig. 4B and F). This evidence concerns the gene PLCB1 and myelodysplastic syndrome.